Next Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Next Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-995	Closed	-$7K	–	201
2019 Q3	$7K	Hold	995	–	–	﹤0.01%	241
2019 Q2	$9K	Hold	995	–	–	0.01%	473
2019 Q1	$16K	Hold	995	–	–	0.01%	200
2018 Q4	$15K	Buy	+995	New	+$20.4K	0.01%	181

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Next Capital Management's TEVA Position: Q4 2019 in Review

Next Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 995 shares — an estimated $7K sold.

Next Capital Management first reported a position in TEVA in Q4 2018 and held it in 4 quarters. The position peaked at $16K in Q1 2019. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Next Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Next Capital Management sold 995 Teva Pharmaceuticals shares in Q4 2019, an estimated $7K.
Next Capital Management first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Next Capital Management's Teva Pharmaceuticals position peaked at $16K in Q1 2019.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Next Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.